Fadi Haddad, MD, discusses the use of asciminib in patients with chronic myeloid leukemia.
Fadi Haddad, MD
Advertisement
Fadi G. Haddad, MD, is assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
Articles by Fadi Haddad, MD
A recent study highlights asciminib's effectiveness in treating newly diagnosed CML, showing promising molecular response rates and safety profiles.
Patients with chronic myeloid leukemia can have a near-normal life expectation when treated with BCR::ABL1 tyrosine kinase inhibitors.
Fadi Haddad, MD, discusses the background of a phase 2 study of blinatumomab in combination with ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fadi Haddad, MD, discusses the key points from the presentation he gave during the Tenth Annual Meeting of the Society of Hematologic Oncology.
Advertisement
Latest Updated Articles
Dr Fadi Haddad Advises Clinicians on Asciminib Treatment in CMLPublished: December 11th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5
